PATHMEDIUM SIGNALFINANCIAL10-K

PATH delivered solid double-digit growth across revenue, gross profit, and operating cash flow while reducing share repurchases and expanding its AI capabilities strategy.

The company demonstrates healthy operational momentum with revenue growing 12.7% and operating cash flow expanding 15.8%, indicating strong cash generation from core business activities. However, the 15.8% reduction in share buybacks suggests management may be conserving cash or shifting capital allocation priorities, which warrants monitoring given the concurrent increase in current liabilities.

Comparing 2026-03-25 vs 2025-03-24View on EDGAR →
FINANCIAL ANALYSIS

PATH exhibited balanced growth with revenue advancing 12.7% to $1.6B and gross profit expanding proportionally at 13.3% to $1.3B, maintaining healthy margins. Operating cash flow strengthened notably to $371.2M, while the company reduced share repurchases to $329.1M and increased capital expenditures modestly to $19.0M. The balance sheet expanded across key metrics with total assets reaching $3.2B and stockholders equity growing to $2.1B, though current liabilities also increased to $905.4M, reflecting the company's overall business expansion.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+27.6%
$14.9M→$19.0M

Capex increased 27.6% — ongoing investment in capacity or infrastructure for future growth.

Operating Cash Flow
Cash Flow
+15.8%
$320.6M→$371.2M

Operating cash flow grew 15.8% — strong conversion of earnings to cash, healthy business fundamentals.

Share Buybacks
Cash Flow
-15.8%
$390.8M→$329.1M

Buyback activity reduced 15.8% — capital being redeployed elsewhere or cash conservation underway.

Gross Profit
P&L
+13.3%
$1.2B→$1.3B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Current Liabilities
Balance Sheet
+13.3%
$798.9M→$905.4M

Current liabilities rose 13.3% — increased short-term obligations, watch current ratio.

Stockholders Equity
Balance Sheet
+12.8%
$1.8B→$2.1B

Equity base grew 12.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
+12.7%
$1.4B→$1.6B

Revenue growing 12.7% — solid top-line momentum, watch margins for quality of growth.

Total Assets
Balance Sheet
+11%
$2.9B→$3.2B

Asset base grew 11% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-24
ADDED
As of March 20, 2026, the registrant had 459,231,166 shares of Class A common stock and 64,690,706 shares of Class B common stock outstanding.
Such statements are inherently uncertain and may involve significant assumptions, and investors are cautioned not to unduly rely on these statements.
As a result, we may not be able to accurately predict future results, and our past results may not be indicative of our future performance.
If we fail to meet the expectations of securities analysts or investors with respect to our results of operations, our stock price could decline.
Declines or significant delays in renewals or purchases of additional licenses and products by our customers have from time to time harmed and could in the future harm our operating results.
+7 more — sign up free →
REMOVED
As of March 20, 2025, the registrant had 474,040,169 shares of Class A common stock and 77,452,748 shares of Class B common stock outstanding.
Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information.
Such statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
Our past results may not be indicative of our future performance.
We expect fluctuations in our financial results, making it difficult to project future results, and if we fail to meet the expectations of securities analysts or investors with respect to our results of operations, our stock price could decline.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →